Now available ZYNYZ™ 

ZYNYZ™ (retifanlimab-dlwr) is indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and duration of response.